Immunome (IMNM) Short Interest Ratio & Short Volume → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free IMNM Stock Alerts $13.83 -0.57 (-3.96%) (As of 05/17/2024 08:53 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Immunome Short Interest DataCurrent Short Volume2,650,000 sharesPrevious Short Volume3,850,000 sharesChange Vs. Previous Month-31.17%Dollar Volume Sold Short$64.13 millionShort Interest Ratio / Days to Cover4.2Last Record DateFebruary 29, 2024Outstanding Shares59,970,000 sharesPercentage of Shares Shorted4.42%Today's Trading Volume699,000 sharesAverage Trading Volume737,718 sharesToday's Volume Vs. Average95% Short Selling Immunome ? Sign up to receive the latest short interest report for Immunome and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatIMNM Short Interest Over TimeIMNM Days to Cover Over TimeIMNM Percentage of Float Shorted Over Time Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. Immunome Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 2/29/20242,650,000 shares $64.13 million -31.2%N/A4.2 $24.20 2/15/20243,850,000 shares $86.70 million +12.9%N/A7.1 $22.52 1/31/20243,410,000 shares $56.50 million +71.4%N/A9.2 $16.57 1/15/20241,990,000 shares $26.19 million +8.2%N/A8.7 $13.16 12/31/20231,840,000 shares $19.69 million +171.4%N/A11.1 $10.70 12/15/2023678,100 shares $5.11 million +24.6%N/A5.1 $7.54 Get the Latest News and Ratings for IMNM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Immunome and its competitors with MarketBeat's FREE daily newsletter. 11/30/2023544,100 shares $4.06 million +27.1%N/A7.9 $7.46 11/15/2023428,200 shares $3.40 million +96.4%N/A7.4 $7.95 10/31/2023218,000 shares $1.92 million +10.3%N/A4.6 $8.80 10/15/2023197,700 shares $1.78 million -10.3%N/A4.5 $8.99 9/30/2023220,500 shares $1.84 million -3.0%2.9%4.5 $8.35 9/15/2023227,200 shares $1.65 million +5.3%2.7%0.9 $7.26 8/31/2023215,800 shares $1.39 million +0.1%2.6%0.9 $6.45 8/15/2023215,500 shares $1.61 million -11.7%2.6%0.9 $7.45 7/31/2023244,000 shares $1.75 million +17.4%2.9%1 $7.16 7/15/2023207,800 shares $1.61 million +70.9%2.6%0.8 $7.77 6/30/2023121,600 shares $961,856.00 -14.9%1.5%0.5 $7.91 6/15/2023142,900 shares $763,086.00 -3.1%1.5%5 $5.34 5/31/2023147,500 shares $772,900.00 +5.9%1.5%4.7 $5.24 5/15/2023139,300 shares $866,446.00 -30.0%1.5%4.1 $6.22 4/30/2023198,900 shares $952,731.00 +8.6%2.1%5.6 $4.79 4/15/2023183,200 shares $883,024.00 +12.6%1.9%4.5 $4.82 3/31/2023162,700 shares $811,873.00 +25.6%1.7%3.2 $4.99 3/15/2023129,500 shares $609,945.00 -11.2%1.4%1.5 $4.71 2/28/2023145,800 shares $666,306.00 +9.3%1.5%1.7 $4.57 2/15/2023133,400 shares $729,698.00 +0.9%1.4%1.6 $5.47 1/31/2023132,200 shares $699,338.00 +15.9%1.4%1.7 $5.29 1/15/2023114,100 shares $456,400.00 +117.8%1.2%1.6 $4.00 12/30/202252,400 shares $115,804.00 -13.8%0.6%0.9 $2.21 12/15/202260,800 shares $234,080.00 -20.3%0.6%3.6 $3.85 11/30/202276,300 shares $329,997.50 +14.1%0.8%5 $4.33 11/15/202266,900 shares $278,304.00 +43.9%0.7%4 $4.16 10/31/202246,500 shares $202,740.00 +10.2%0.5%2.3 $4.36 10/15/202242,200 shares $200,872.00 -8.7%0.4%1.8 $4.76 9/30/202246,200 shares $205,128.00 +9.7%0.5%1.9 $4.44 9/15/202242,100 shares $214,289.00 +7.4%0.4%1.2 $5.09 8/31/202239,200 shares $225,008.00 -0.3%0.4%1.1 $5.74 8/15/202239,300 shares $208,290.00 -13.8%0.4%1 $5.30 7/31/202245,600 shares $177,156.00 -13.0%0.5%1 $3.89 7/15/202252,400 shares $205,932.00 -6.4%0.6%0.9 $3.93Shocking $16T Elon Musk Crypto Leak (Ad)Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. IMNM Short Interest - Frequently Asked Questions What is Immunome's current short interest? Short interest is the volume of Immunome shares that have been sold short but have not yet been closed out or covered. As of February 29th, investors have sold 2,650,000 shares of IMNM short. Learn More on Immunome's current short interest. What is a good short interest ratio for Immunome? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IMNM shares currently have a short interest ratio of 4.0. Learn More on Immunome's short interest ratio. Is Immunome's short interest increasing or decreasing? Immunome saw a decline in short interest in February. As of February 29th, there was short interest totaling 2,650,000 shares, a decline of 31.2% from the previous total of 3,850,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Immunome's short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Immunome: ABIVAX Société Anonyme (0.12%), 89bio, Inc. (10.93%), ARS Pharmaceuticals, Inc. (15.81%), OPKO Health, Inc. (26.42%), Centessa Pharmaceuticals plc (2.99%), Pliant Therapeutics, Inc. (12.51%), Liquidia Co. (10.62%), Zentalis Pharmaceuticals, Inc. (24.64%), Ocular Therapeutix, Inc. (13.61%), Arcutis Biotherapeutics, Inc. (18.74%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($4.39 billion), General Motors ($3.88 billion), Super Micro Computer, Inc. ($3.51 billion), Charter Communications, Inc. ($3.22 billion), Occidental Petroleum Co. ($3.13 billion), Tractor Supply ($2.76 billion), Coinbase Global, Inc. ($2.63 billion), Suncor Energy Inc. ($2.48 billion), Moderna, Inc. ($2.04 billion), and Royal Caribbean Cruises Ltd. ($1.87 billion). View all of the most shorted stocks. What does it mean to sell short Immunome stock? Short selling IMNM is an investing strategy that aims to generate trading profit from Immunome as its price is falling. IMNM shares are trading down $0.57 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Immunome? A short squeeze for Immunome occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of IMNM, which in turn drives the price of the stock up even further. How often is Immunome's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IMNM, twice per month. The most recent reporting period available is February, 29 2024. More Short Interest Resources from MarketBeat Related Companies: ABIVAX Société Anonyme Short Interest Data 89bio Short Interest Data ARS Pharmaceuticals Short Interest Data OPKO Health Short Interest Data Centessa Pharmaceuticals Short Interest Data Pliant Therapeutics Short Interest Data Liquidia Short Interest Data Zentalis Pharmaceuticals Short Interest Data Ocular Therapeutix Short Interest Data Arcutis Biotherapeutics Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:IMNM) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldDoes this make you sick?Allegiance GoldUrgent Nvidia WarningAltimetryThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarShocking: One AI startup's revenue could surge 4,735%Manward PressGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders